Vicarious Surgical (RBOT) Income from Continuing Operations (2020 - 2025)
Vicarious Surgical's (RBOT) quarterly Income from Continuing Operations came in at 11058000.0 in Q3 2025, up 35.3% year-on-year from 8172992.48 in Q3 2024, and up 16.32% on a QoQ basis from 13215000.0 in Q2 2025.
Vicarious Surgical (RBOT) Income from Continuing Operations (2020 - 2025) Analysis & Trends
Vicarious Surgical (RBOT) has 6 years of Income from Continuing Operations data on file, last reported at 11058000.0 in Q3 2025.
- On a quarterly basis, Income from Continuing Operations rose 35.3% year-over-year to 11058000.0 in Q3 2025; TTM through Sep 2025 was 53593000.0, a 14.12% increase from a year earlier, with the FY2024 full-year figure at 63223000.0, up 11.04% from the prior year.
- Income from Continuing Operations for Q3 2025 stood at 11058000.0, up from 13215000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for RBOT reached as high as 42527000.0 in Q1 2022 and fell as low as 45124000.0 in Q3 2021.
- Historically, Income from Continuing Operations has averaged 10737421.05 across 5 years, with a median of 13926000.0 in 2024.
- Across the five-year window, Income from Continuing Operations slumped 24757.7% in 2021 and surged 912.98% in 2022, its largest moves.
- Year by year, Income from Continuing Operations stood at 21786000.0 in 2021, then slumped by 151.32% to 11180000.0 in 2022, then declined by 17.27% to 13111000.0 in 2023, then fell by 6.22% to 13926000.0 in 2024, then advanced by 20.59% to 11058000.0 in 2025.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 11058000.0 in Q3 2025, 13215000.0 in Q2 2025, and 15394000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Vicarious Surgical | 654,984.55 | -9.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -11.06 Mn |
| Jun 30, 2025 | -13.22 Mn |
| Mar 31, 2025 | -15.39 Mn |
| Dec 31, 2024 | -13.93 Mn |
| Sep 30, 2024 | -17.09 Mn |
| Jun 30, 2024 | -15.21 Mn |
| Mar 31, 2024 | -17.00 Mn |
| Dec 31, 2023 | -13.11 Mn |
| Sep 30, 2023 | -15.70 Mn |
| Jun 30, 2023 | -15.33 Mn |
| Mar 31, 2023 | -26.92 Mn |
| Dec 31, 2022 | -11.18 Mn |
| Sep 30, 2022 | -24.74 Mn |
| Jun 30, 2022 | -1.45 Mn |
| Mar 31, 2022 | 42.53 Mn |
| Dec 31, 2021 | 21.79 Mn |
| Sep 30, 2021 | -45.12 Mn |
| Jun 30, 2021 | -6.64 Mn |
| Mar 31, 2021 | -5.23 Mn |
| Dec 31, 2020 | -3.78 Mn |